All chapters

CHAPTER 10

Open Access to the KCNQ Channel: Retigabine and Second Generation M-current Openers

In 2011, Retigabine (Ezogabine; Valeant Pharmaceuticals/GlaxoSmithKline), an opener of KCNQ (Kv7) potassium channels, was approved for the adjunctive treatment of partial-onset seizures in adult patients. In this chapter, we review the story of retigabine, from identification as a novel anticonvulsant through to clinical testing, and detail the ongoing work to identify a second generation of KCNQ channel openers.

Publication details

Print publication date
18 Sep 2014
Copyright year
2015
Print ISBN
978-1-84973-186-7
PDF eISBN
978-1-84973-508-7
ePub eISBN
978-1-78262-307-6

From the book series:
Drug Discovery